Highly polymorphic human leukocyte antigen (HLA) genes are responsible for fine-tuning the adaptive immune system. High-resolution HLA typing is important for the treatment of autoimmune and infectious diseases. Additionally, it is routinely performed for identifying matched donors in transplantation medicine. Although many HLA typing approaches have been developed, the complexity, low-efficiency and high-cost of current HLA-typing assays limit their application in population-based high-throughput HLA typing for donors, which is required for creating large-scale databases for transplantation and precision medicine. Here, we present a cost-efficient Saturated Tiling Capture Sequencing (STC-Seq) approach to capturing 14 HLA class I and II genes. The highly efficient capture (an approximately 23,000-fold enrichment) of these genes allows for simplified allele calling. Tests on five genes (HLA-A/B/C/DRB1/DQB1) from 31 human samples and 351 datasets using STC-Seq showed results that were 98% consistent with the known two sets of digitals (field1 and field2) genotypes. Additionally, STC can capture genomic DNA fragments longer than 3 kb from HLA loci, making the library compatible with the third-generation sequencing. STC-Seq is a highly accurate and cost-efficient method for HLA typing which can be used to facilitate the establishment of population-based HLA databases for the precision and transplantation medicine.
12 December 2023 in Molecular & Cellular Proteomics
Large-scale omics studies have generated a wealth of mass spectrometry-based proteomics data, which provide additional insights into disease biology spanning genomic boundaries. However, there is a notable lack of web-based analysis and visualization tools that facilitate the reutilization of these data. Given this challenge, we present iProPhos, a user-friendly web server to deliver interactive and customizable functionalities. iProPhos incorporates a large number of samples, including 1444 tumor samples and 746 normal samples across 12 cancer types, sourced from the Clinical Proteomic Tumor Analysis Consortium. Additionally, users can also upload their own proteomics/phosphoproteomics data for analysis and visualization. In iProPhos, users can perform profiling plotting and differential expression, patient survival, clinical feature-related, and correlation analyses, including protein-protein, mRNA-protein, and kinase-substrate correlations. Furthermore, functional enrichment, protein-protein interaction network, and kinase-substrate enrichment analyses are accessible. iProPhos displays the analytical results in interactive figures and tables with various selectable parameters. It is freely accessible at http://longlab-zju.cn/iProPhos without login requirement. We present two case studies to demonstrate that iProPhos can identify potential drug targets and upstream kinases contributing to site-specific phosphorylation. Ultimately, iProPhos allows end-users to leverage the value of big data in cancer proteomics more effectively and accelerates the discovery of novel therapeutic targets.
Gliomas are the most prevalent and aggressive neoplasms of the central nervous system, representing a major challenge for effective treatment and patient prognosis. This study identifies the proteasome subunit beta type-8 (PSMB8/LMP7) as a promising prognostic biomarker for glioma. Using a multiparametric radiomic model derived from preoperative magnetic resonance imaging (MRI), we accurately predicted PSMB8 expression levels. Notably, radiomic prediction of poor prognosis was highly consistent with elevated PSMB8 expression. Our findings demonstrate that PSMB8 depletion not only suppressed glioma cell proliferation and migration but also induced apoptosis via activation of the transforming growth factor beta (TGF-β) signaling pathway. This was supported by downregulation of key receptors (TGFBR1 and TGFBR2). Furthermore, interference with PSMB8 expression impaired phosphorylation and nuclear translocation of SMAD2/3, critical mediators of TGF-β signaling. Consequently, these molecular alterations resulted in reduced tumor progression and enhanced sensitivity to temozolomide (TMZ), a standard chemotherapeutic agent. Overall, our findings highlight PSMB8's pivotal role in glioma pathophysiology and its potential as a prognostic marker. This study also demonstrates the clinical utility of MRI radiomics for preoperative risk stratification and pre-diagnosis. Targeted inhibition of PSMB8 may represent a therapeutic strategy to overcome TMZ resistance and improve glioma patient outcomes.
Background: Prolyl 4-hydroxylase subunit beta (P4HB) has been linked to glioma progression and treatment resistance; however, its role in the tumor microenvironment regulation remains unclear. Materials and Methods: A total of 90 human glioma samples and 30 normal traumatic brain injury (TBI) tissues from patients undergoing surgical resection were collected from the First Affiliated Hospital of Zhengzhou University for immunohistochemical (IHC) staining. The signaling pathway mechanism regulating prognosis and tumor proliferation was explored through bioinformatics analysis and functional assays via P4HB knockdown. Results: The IHC analysis of 90 glioma and 30 TBI tissues revealed that P4HB expression correlated with tumor malignancy, especially the WHO grade 4 and grade 2 ( P < 0.0001). Furthermore, transcriptomic data analysis identified P4HB as a prognostic marker associated with poor survival and tumor-associated macrophage infiltration ( P < 0.05 in all cohorts). Using shRNA lentiviral constructs, stable P4HB knockdown glioblastoma (GBM) cell lines were generated. mRNA sequencing revealed significant downregulation of the interleukin (IL)-6/signal transducer and activator of transcription 3 (IL-6/STAT3) signaling axis. Functional studies showed that P4HB deficiency resulted in reduced IL-6 secretion ( P < 0.0001), suppressed M2 polarization of tumor-associated microglia, and inhibited glioma cell growth both in vitro and in vivo , with IL-6 neutralization recapitulating these effects. Mechanistically, P4HB promoted STAT3 phosphorylation in microglia, driving their pro-tumorigenic M2 phenotype. Conclusion: These findings establish P4HB as a regulator of glioma progression via IL-6/STAT3-mediated microglial polarization, highlighting its potential as a therapeutic target for GBM.